03.02.04 Other equipment for immunochemistry and immunology
Other equipment for immunochemistry and immunology
Product category: Diagnostic tests for cancer
Serum tumor markers is a term commonly used to refer to molecules that can be detected in a blood sample by immunochemical methods. Tumor markers are produced either by the tumor (cancer) itself or by the body in response to the presence of cancer or certain non-cancerous benign ) conditions.
30 years of experience in IVD (kits and instrumentation) DIAsource ImmunoAssays (formerly BioSource), an international diagnostic company based in Belgium, develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.
We are committed to Vitamin D, including IVD and RUO Products. Our panel of assays allows the performant detection and measurement of various forms of Vitamin D metabolites : 25OH Vitamin D, 1,25(OH)2 Vitamin D.
Constantly looking for new technologies and applications, we put our expertise in the development of new antibodies and assays to measure relevant biomarkers. We are strengthening our position in the diagnostic market by validating our ELISA assays on our open automate. These innovation mark a turning point for our company, and makes of DIAsource, already renowned in the RIA market, a complete diagnostic provider.
We also provide selected instrumentation : we offer Elisa reader, washer and shaker, along with open and closed fully automated Elisa platforms helping our customers to automate their tests.
Present in more than 75 countries through his professional network of 80 distributors, DIAsource also sells directly his own products and products from other selected manufacturers to IVD laboratories in some European countries.
DIAsource ImmunoAssays SA, acquired, in September 2017, the full assets of Viro-Immun Diagnostics GmbH, the German company specialized since 30 years in the development and manufacture of laboratory diagnostics for medical diagnosis of infectious and autoimmune diseases.
Beginning September 2017, Biovendor – Laboratorní medicína a.s. (BioVendor) acquired 100% of the shares of DIAsource ImmunoAssays SA from the Australian stock listed company Anteo Diagnostics (ASX: ADO). Anteo Diagnostics had acquired DIAsource in January 2016.